Compare Recursion Pharmaceuticals Inc (RXRX) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ProShares UltraPro QQQ ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while ProShares UltraPro QQQ ETF trades at $71.24. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | TQQQ | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $6.79 | $87.22 |
52-Week Low | $2.84 | $37.89 |
Enterprise Value | $946.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
TQQQ trades at $67.65, up 0.18% on the day, with a bearish technical signal driven by moving averages. The ETF faces structural costs and volatility risks, as highlighted in recent news. Key support lies at $66, with resistance at $69. Recent articles emphasize the amplified downside potential during market selloffs, questioning the long-term viability of leveraged strategies.
Outlook remains cautious due to high volatility and compounding costs. Opportunities exist for tactical traders during uptrends, but risks include severe drawdowns and daily rebalancing effects. Investors should weigh the 3x leverage against potential wealth destruction in downturns, as seen in 2022's 81% drop versus Nasdaq's 33% decline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
